idelalisib
Showing 26 - 41 of 41
Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma Trial in Palo Alto, New York (Idelalisib)
Completed
- Indolent Non-Hodgkin's Lymphoma
- +3 more
- Idelalisib
-
Palo Alto, California
- +1 more
Oct 19, 2018
DLBCL, Mediastinal B-cell Lymphoma Trial in Worldwide (Idelalisib, Rituximab, Ifosfamide)
Withdrawn
- Diffuse Large B-Cell Lymphoma
- Mediastinal B-cell Lymphoma
- Idelalisib
- +4 more
-
Lille, France
- +6 more
Dec 7, 2018
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) Trial in United States (Idelalisib, Rituximab)
Terminated
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Idelalisib
- Rituximab
-
La Jolla, California
- +5 more
Oct 19, 2018
Chronic Lymphocytic Leukemia Trial in Worldwide (Idelalisib, Rituximab, Placebo to match idelalisib)
Completed
- Chronic Lymphocytic Leukemia
- Idelalisib
- +2 more
-
Huntsville, Alabama
- +71 more
May 1, 2019
Chronic Lymphocytic Leukemia Trial in Worldwide (Idelalisib, Ofatumumab)
Terminated
- Chronic Lymphocytic Leukemia
- Idelalisib
- Ofatumumab
-
Duarte, California
- +79 more
Aug 5, 2019
Chronic Lymphocytic Leukemia Trial in Worldwide (Idelalisib, Chlorambucil, Obinutuzumab)
Terminated
- Chronic Lymphocytic Leukemia
- Idelalisib
- +2 more
-
Santa Barbara, California
- +17 more
Oct 19, 2018
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Trial in Portland (drug, device, biological)
Completed
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Cyclophosphamide
- +16 more
-
Portland, OregonOHSU Knight Cancer Institute
May 21, 2020
B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion Trial in Worldwide (Idelalisib, Rituximab)
Terminated
- B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
- Idelalisib
- Rituximab
-
Tucson, Arizona
- +55 more
Oct 19, 2018
Relapsed/Refractory Mantle Cell Lymphoma Trial in United States (lenalidomide, idelalisib)
Completed
- Relapsed/Refractory Mantle Cell Lymphoma
- lenalidomide
- idelalisib
-
Chicago, Illinois
- +3 more
Jan 26, 2018
Chronic Lymphocytic Leukemia Trial in Worldwide (Idelalisib, Bendamustine, Rituximab)
Terminated
- Chronic Lymphocytic Leukemia
- Idelalisib
- +3 more
-
Fullerton, California
- +90 more
Oct 19, 2018
Indolent Non-Hodgkin's Lymphomas Trial in Worldwide (Placebo, Rituximab, Idelalisib)
Terminated
- Indolent Non-Hodgkin's Lymphomas
- Placebo
- +2 more
-
Huntsville, Alabama
- +102 more
Oct 19, 2018
Amyloidosis Trial in Boston (Idelalisib)
Terminated
- Amyloidosis
- Idelalisib
-
Boston, MassachusettsBoston Medical Center
Aug 23, 2017
Non Small Cell Lung Cancer, Metastasis, Recurrence Trial in Augusta (Pembrolizumab, Idelalisib)
Unknown status
- Non Small Cell Lung Cancer
- +2 more
- Pembrolizumab
- Idelalisib
-
Augusta, GeorgiaGeorgia Cancer Center at Augusta University
Sep 27, 2017
Indolent Non-Hodgkin's Lymphomas Trial in Worldwide (Idelalisib, Rituximab, Bendamustine)
Terminated
- Indolent Non-Hodgkin's Lymphomas
- Idelalisib
- +3 more
-
Huntsville, Alabama
- +143 more
Oct 19, 2018
Chronic Lymphocytic Leukemia (CLL) Trial in Worldwide (Idelalisib, Rituximab)
Approved for marketing
- Chronic Lymphocytic Leukemia (CLL)
- Idelalisib
- Rituximab
-
La Jolla, California
- +7 more
Oct 27, 2014